{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:16:41Z","timestamp":1762507001773,"version":"3.41.2"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2016YFC1201000","2016YFC1200405","2016YFC1202901"],"award-info":[{"award-number":["2016YFC1201000","2016YFC1200405","2016YFC1202901"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81590762"],"award-info":[{"award-number":["81590762"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Ebola virus (EBOV), the causative pathogen of the deadly Ebola virus disease (EVD), can be transmitted via contact with EVD patients, including sexual contact with EVD survivors. At present, no licensed vaccine or therapeutic is available. In this study, we compared eight anhydride-modified proteins for their entry-inhibitory activity against the pseudovirus (PsV) carrying the envelope glycoprotein (GP) of the EBOV Zaire or Sudan species (Zaire PsV and Sudan PsV, respectively). We found that 3-hydroxyphthalic anhydride-modified human serum albumin (HP-HSA) was the most effective in inhibiting the entry of both Zaire PsV and Sudan PsV, with the 50% effective concentration being at the nanomolar level and with HP-HSA being more potent than EBOV-neutralizing antibody MIL77-2 (4G7, a component antibody of the ZMapp drug cocktail). The combination of HP-HSA and MIL77-2 exhibited a synergistic effect. HP-HSA had no obvious\n            <jats:italic>in vitro<\/jats:italic>\n            or\n            <jats:italic>in vivo<\/jats:italic>\n            toxicity. The EBOV PsV entry-inhibitory activity of HP-HSA remained intact after storage at 45\u00b0C for 8 weeks, suggesting that HP-HSA has the potential for worldwide use, including tropical regions in African countries, as either a therapeutic to treat EBOV infection or a prophylactic microbicide to prevent the sexual transmission of EBOV.\n          <\/jats:p>","DOI":"10.1128\/aac.02168-16","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T01:50:11Z","timestamp":1486432211000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles"],"prefix":"10.1128","volume":"61","author":[{"given":"Haoyang","family":"Li","sequence":"first","affiliation":[{"name":"Key Lab of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[{"name":"Key Lab of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Xia","sequence":"additional","affiliation":[{"name":"Key Lab of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Yu","sequence":"additional","affiliation":[{"name":"Key Lab of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Lab of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lv","sequence":"additional","affiliation":[{"name":"Institute of Basic Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Information Center for Life Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Key Lab of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China"},{"name":"Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[{"name":"Key Lab of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-015-0480-y"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60667-8"},{"key":"e_1_3_3_4_2","volume-title":"Fields virology","author":"Knipe DM","year":"2013","unstructured":"Knipe DM HowleyPM CohenJI GriffinDE LambRA MartinMA RacanielloVR RoizmanB (ed). 2013. Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_3_5_2","volume-title":"Ebola situation report","author":"WHO","year":"2016","unstructured":"WHO. 2016. Ebola situation report. WHO, Geneva, Switzerland. http:\/\/www.who.int\/csr\/disease\/ebola\/en\/."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003652"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83162"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83111"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw078"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511410"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509773"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2014.11.012"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13777"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.022"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.030511"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.AID-0026-2014"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30175-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw202"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa5597"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Vogel\nG KupferschmidtK. 2015. In setback for potential Ebola drug company halts trial. Science. doi:10.1126\/science.aac6876.","DOI":"10.1126\/science.aac6876"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis921"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15012-X"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/v7020798"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2013.03.003"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01046-09"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","unstructured":"Guo\nX QiuL WangY WangY WangQ SongL LiY HuangK DuX FanW JiangS WangQ LiH YangY MengY ZhuY LuL JiangS. 2016. A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. Microbes Infect18:148\u2013152. doi:10.1016\/j.micinf.2015.10.004.","DOI":"10.1016\/j.micinf.2015.10.004"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0296-230"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24439"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07082"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414164111"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9875"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001110"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.044"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03156-14"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/v4020258"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-6-75"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056265"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00543-16"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.88"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00406-16"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir326"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb0509-510"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)40971-9"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1109736108"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606631103"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-37"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2150"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.04.014"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.10.5266-5270.2002"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.10.4933-4937.2000"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000971"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00644-10"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000223287.46097.4b"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20160089"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02168-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02168-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:54:17Z","timestamp":1645476857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02168-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1128\/AAC.02168-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02168-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"2016-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02168-16"}}